{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T05:31:51Z","timestamp":1793770311100,"version":"4.6.1"},"reference-count":70,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T00:00:00Z","timestamp":1791590400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002858","name":"China Postdoctoral Science Foundation","doi-asserted-by":"publisher","award":["2024M763916"],"award-info":[{"award-number":["2024M763916"]}],"id":[{"id":"10.13039\/501100002858","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003453","name":"Natural Science Foundation of Guangdong Province","doi-asserted-by":"publisher","award":["2025A1515012798"],"award-info":[{"award-number":["2025A1515012798"]}],"id":[{"id":"10.13039\/501100003453","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Life Sciences"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.lfs.2026.124723","type":"journal-article","created":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T06:50:15Z","timestamp":1791269415000},"page":"124723","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Therapeutic engineering of the IL-18-IL-18BP axis for precision cancer immunotherapy"],"prefix":"10.1016","volume":"406","author":[{"given":"Yan","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meiji","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingyue","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ge","family":"Shan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zheng","family":"Xiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhinan","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.lfs.2026.124723_bb0005","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/j.cell.2017.01.017","article-title":"Primary, adaptive, and acquired resistance to cancer immunotherapy","volume":"168","author":"Sharma","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.lfs.2026.124723_bb0010","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1038\/s41591-018-0014-x","article-title":"Understanding the tumor immune microenvironment (TIME) for effective therapy","volume":"24","author":"Binnewies","year":"2018","journal-title":"Nat. Med."},{"key":"10.1016\/j.lfs.2026.124723_bb0015","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/bjc.2017.434","article-title":"Mechanisms of resistance to immune checkpoint inhibitors","volume":"118","author":"Jenkins","year":"2018","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.lfs.2026.124723_bb0020","doi-asserted-by":"crossref","first-page":"4","DOI":"10.3389\/fimmu.2013.00289","article-title":"Interleukin-18 and IL-18 binding protein","volume":"4","author":"Dinarello","year":"2013","journal-title":"Front. Immunol."},{"key":"10.1016\/j.lfs.2026.124723_bb0025","doi-asserted-by":"crossref","first-page":"4265","DOI":"10.1158\/1078-0432.CCR-06-0121","article-title":"Clinical and biological effects of recombinant human interleukin-18 administered by intravenous infusion to patients with advanced cancer","volume":"12","author":"Robertson","year":"2006","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.lfs.2026.124723_bb0030","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1038\/s41586-020-2422-6","article-title":"IL-18BP is a secreted immune checkpoint and barrier to IL-18 immunotherapy","volume":"583","author":"Zhou","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.lfs.2026.124723_bb0035","article-title":"IL-18-mediated tumor immune evasion","volume":"48","author":"Li","year":"2026","journal-title":"Curr. Issues Mol. Biol."},{"key":"10.1016\/j.lfs.2026.124723_bb0040","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-009716","article-title":"Durable antitumor response via an oncolytic virus encoding decoy-resistant IL-18","volume":"12","author":"Cheng","year":"2024","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.lfs.2026.124723_bb0045","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.molmed.2023.01.006","article-title":"Gene-based delivery of immune-activating cytokines for cancer treatment","volume":"29","author":"Rossari","year":"2023","journal-title":"Trends Mol. Med."},{"key":"10.1016\/j.lfs.2026.124723_bb0050","doi-asserted-by":"crossref","DOI":"10.3390\/ijms252413505","article-title":"IL-18 and IL-18BP: a unique dyad in health and disease","volume":"25","author":"Novick","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.lfs.2026.124723_bb0055","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1038\/s41584-023-01053-w","article-title":"Biological and clinical roles of IL-18 in inflammatory diseases","volume":"20","author":"Landy","year":"2024","journal-title":"Nat. Rev. Rheumatol."},{"key":"10.1016\/j.lfs.2026.124723_bb0060","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines10071750","article-title":"Interleukin-18 binding protein in immune regulation and autoimmune diseases","volume":"10","author":"Park","year":"2022","journal-title":"Biomedicines"},{"key":"10.1016\/j.lfs.2026.124723_bb0065","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1038\/s41577-024-01075-9","article-title":"Inflammasome components as new therapeutic targets in inflammatory disease","volume":"25","author":"Coll","year":"2025","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.lfs.2026.124723_bb0070","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1038\/s41423-025-01358-8","article-title":"IL-1 family cytokines in inflammation and immunity","volume":"22","author":"Garlanda","year":"2025","journal-title":"Cell. Mol. Immunol."},{"key":"10.1016\/j.lfs.2026.124723_bb0075","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-010545","article-title":"Weal and woe of interleukin-18 in the t cell therapy of cancer","volume":"13","author":"Kessel","year":"2025","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.lfs.2026.124723_bb0080","doi-asserted-by":"crossref","DOI":"10.1016\/j.smim.2025.101997","article-title":"Unlocking IL-18: a hidden key in cancer immunity","volume":"80","author":"Sepehri-Manesh","year":"2025","journal-title":"Semin. Immunol."},{"key":"10.1016\/j.lfs.2026.124723_bb0085","first-page":"287","article-title":"Effect of IL-18 on expansion of gammadelta t cells stimulated by zoledronate and IL-2","volume":"33","author":"Li","year":"2010","journal-title":"J. Immunother. (Hagerstown, Md.: 1997)"},{"key":"10.1016\/j.lfs.2026.124723_bb0090","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12010130","article-title":"In the absence of a TCR signal IL-2\/IL-12\/18-stimulated \u03b3\u03b4 t cells demonstrate potent anti-tumoral function through direct killing and senescence induction in cancer cells","volume":"12","author":"Schilbach","year":"2020","journal-title":"Cancers"},{"key":"10.1016\/j.lfs.2026.124723_bb0095","article-title":"IL-18 receptor marks functional CD8(+) t cells in non-small cell lung cancer","volume":"6","author":"Timperi","year":"2017","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.lfs.2026.124723_bb0100","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1158\/2326-6066.CIR-22-0398","article-title":"IL18 receptor signaling regulates tumor-reactive CD8+ t-cell exhaustion via activation of the IL2\/STAT5\/mTOR pathway in a pancreatic cancer model","volume":"11","author":"Lutz","year":"2023","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.lfs.2026.124723_bb0105","doi-asserted-by":"crossref","first-page":"4653","DOI":"10.1158\/0008-5472.CAN-12-4366","article-title":"IL-18-primed helper NK cells collaborate with dendritic cells to promote recruitment of effector CD8+ t cells to the tumor microenvironment","volume":"73","author":"Wong","year":"2013","journal-title":"Cancer Res."},{"key":"10.1016\/j.lfs.2026.124723_bb0110","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.bbmt.2014.01.006","article-title":"Preactivation with IL-12, IL-15, and IL-18 induces CD25 and a functional high-affinity IL-2 receptor on human cytokine-induced memory-like natural killer cells","volume":"20","author":"Leong","year":"2014","journal-title":"Biol. Blood Marrow Transplant."},{"key":"10.1016\/j.lfs.2026.124723_bb0115","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1007\/s00262-020-02553-4","article-title":"IL-12 regulates the expansion, phenotype, and function of murine NK cells activated by IL-15 and IL-18","volume":"69","author":"Oka","year":"2020","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.lfs.2026.124723_bb0120","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1016\/j.cell.2018.01.004","article-title":"NK cells stimulate recruitment of cDC1 into the tumor microenvironment promoting cancer immune control","volume":"172","author":"B\u00f6ttcher","year":"2018","journal-title":"Cell"},{"key":"10.1016\/j.lfs.2026.124723_bb0125","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2025.1533808","article-title":"IL-18-primed NK cells recruit dendritic cells and potentiate tumor therapy mediated by PD-1 blockade","volume":"15","author":"Ohno","year":"2025","journal-title":"Front. Oncol."},{"key":"10.1016\/j.lfs.2026.124723_bb0130","doi-asserted-by":"crossref","first-page":"286","DOI":"10.5483\/BMBRep.2014.47.5.152","article-title":"Enhancement of phagocytosis and cytotoxicity in macrophages by tumor-derived IL-18 stimulation","volume":"47","author":"Xu","year":"2014","journal-title":"BMB Rep."},{"key":"10.1016\/j.lfs.2026.124723_bb0135","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1111\/gtc.12329","article-title":"Inhibition of blood vessel formation in tumors by IL-18-polarized m1 macrophages","volume":"21","author":"Xing","year":"2016","journal-title":"Genes Cells"},{"key":"10.1016\/j.lfs.2026.124723_bb0140","doi-asserted-by":"crossref","first-page":"2373","DOI":"10.1016\/j.ymthe.2024.05.013","article-title":"Granzyme b-activated IL18 potentiates \u03b1\u03b2 and \u03b3\u03b4 CAR t cell immunotherapy in a tumor-dependent manner","volume":"32","author":"Hull","year":"2024","journal-title":"Mol. Ther.: J. Am. Soc. Gene Ther."},{"key":"10.1016\/j.lfs.2026.124723_bb0145","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1158\/0008-5472.1063.65.3","article-title":"Synergistic effects of IL-12 and IL-18 in skewing tumor-reactive t-cell responses towards a type 1 pattern","volume":"65","author":"Li","year":"2005","journal-title":"Cancer Res."},{"key":"10.1016\/j.lfs.2026.124723_bb0150","first-page":"329","article-title":"The dual effects of interleukin-18 in tumor progression","volume":"4","author":"Park","year":"2007","journal-title":"Cell. Mol. Immunol."},{"key":"10.1016\/j.lfs.2026.124723_bb0155","first-page":"296","article-title":"Interleukin 18: friend or foe in cancer","volume":"1836","author":"Palma","year":"2013","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.lfs.2026.124723_bb0160","doi-asserted-by":"crossref","DOI":"10.4110\/in.2024.24.e1","article-title":"Interleukin-18 binding protein (IL-18BP): a long journey from discovery to clinical application","volume":"24","author":"Kim","year":"2024","journal-title":"Immune Netw."},{"key":"10.1016\/j.lfs.2026.124723_bb0165","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.184545","article-title":"Decoy-resistant IL-18 reshapes the tumor microenvironment and enhances rejection by anti\u2013CTLA-4 in renal cell carcinoma","volume":"10","author":"Schoenfeld","year":"2025","journal-title":"JCI Insight"},{"key":"10.1016\/j.lfs.2026.124723_bb0170","doi-asserted-by":"crossref","first-page":"5393","DOI":"10.1158\/0008-5472.CAN-11-0993","article-title":"IL-18 induces PD-1\u2013dependent immunosuppression in cancer","volume":"71","author":"Terme","year":"2011","journal-title":"Cancer Res."},{"key":"10.1016\/j.lfs.2026.124723_bb0175","doi-asserted-by":"crossref","first-page":"2757","DOI":"10.1158\/0008-5472.CAN-11-3379","article-title":"Cancer-induced immunosuppression: IL-18\u2013elicited immunoablative NK cells","volume":"72","author":"Terme","year":"2012","journal-title":"Cancer Res."},{"key":"10.1016\/j.lfs.2026.124723_bb0180","doi-asserted-by":"crossref","first-page":"32722","DOI":"10.18632\/oncotarget.16281","article-title":"Tumor-derived IL-18 induces PD-1 expression on immunosuppressive NK cells in triple-negative breast cancer","volume":"8","author":"Park","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.lfs.2026.124723_bb0185","doi-asserted-by":"crossref","first-page":"5453","DOI":"10.4049\/jimmunol.1401282","article-title":"IL-18 enhances immunosuppressive responses by promoting differentiation into monocytic myeloid-derived suppressor cells","volume":"193","author":"Lim","year":"2014","journal-title":"J. Immunol."},{"key":"10.1016\/j.lfs.2026.124723_bb0190","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.jbo.2017.10.002","article-title":"Inhibition of IL-18-mediated myeloid derived suppressor cell accumulation enhances anti-PD1 efficacy against osteosarcoma cancer","volume":"9","author":"Guan","year":"2017","journal-title":"J. Bone Oncol."},{"key":"10.1016\/j.lfs.2026.124723_bb0195","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1016\/j.ccell.2018.02.007","article-title":"Dysregulated IL-18 is a key driver of immunosuppression and a possible therapeutic target in the multiple myeloma microenvironment","volume":"33","author":"Nakamura","year":"2018","journal-title":"Cancer Cell"},{"key":"10.1016\/j.lfs.2026.124723_bb0200","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2018.00334","article-title":"Interleukin-18 amplifies macrophage polarization and morphological alteration, leading to excessive angiogenesis","volume":"9","author":"Kobori","year":"2018","journal-title":"Front. Immunol."},{"key":"10.1016\/j.lfs.2026.124723_bb0205","doi-asserted-by":"crossref","first-page":"5070","DOI":"10.4049\/jimmunol.162.9.5070","article-title":"IL-18 is a potent coinducer of IL-13 in NK and t cells: a new potential role for IL-18 in modulating the immune response","volume":"162","author":"Hoshino","year":"1999","journal-title":"J. Immunol."},{"key":"10.1016\/j.lfs.2026.124723_bb0210","doi-asserted-by":"crossref","first-page":"2396","DOI":"10.3324\/haematol.2022.282140","article-title":"IL-18 and VEGF-a trigger type 2 innate lymphoid cell accumulation and pro-tumoral function in chronic myeloid leukemia","volume":"108","author":"Fiordi","year":"2023","journal-title":"Haematologica"},{"key":"10.1016\/j.lfs.2026.124723_bb0215","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1080\/14728222.2023.2287574","article-title":"Interleukin-18 in cancer immunology and immunotherapy","volume":"27","author":"Cirella","year":"2023","journal-title":"Expert Opin. Ther. Targets"},{"key":"10.1016\/j.lfs.2026.124723_bb0220","doi-asserted-by":"crossref","DOI":"10.1080\/19420862.2023.2236265","article-title":"Generation and engineering of potent single domain antibody-based bispecific IL-18 mimetics resistant to IL-18BP decoy receptor inhibition","volume":"15","author":"Lipinski","year":"2023","journal-title":"MAbs"},{"key":"10.1016\/j.lfs.2026.124723_bb0225","article-title":"MRNAs encoding IL-12 and a decoy-resistant variant of IL-18 synergize to engineer t cells for efficacious intratumoral adoptive immunotherapy","volume":"4","author":"Olivera","year":"2023","journal-title":"Cell Rep. Med."},{"key":"10.1016\/j.lfs.2026.124723_bb0230","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.839783","article-title":"GMP-compliant manufacturing of TRUCKs: CAR t cells targeting GD2 and releasing inducible IL-18","volume":"13","author":"Glienke","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.lfs.2026.124723_bb0235","doi-asserted-by":"crossref","DOI":"10.1172\/JCI166028","article-title":"IL-18\u2013secreting CAR t cells targeting DLL3 are highly effective in small cell lung cancer models","volume":"133","author":"Jaspers","year":"2023","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.lfs.2026.124723_bb0240","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1182\/blood.2023022293","article-title":"IL-18-secreting multiantigen targeting CAR t cells eliminate antigen-low myeloma in an immunocompetent mouse model","volume":"144","author":"Ng","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.lfs.2026.124723_bb0245","article-title":"Intra-tumoral production of IL18, but not IL12, by TCR-engineered t cells is non-toxic and counteracts immune evasion of solid tumors","volume":"7","author":"Kunert","year":"2017","journal-title":"OncoImmunology"},{"key":"10.1016\/j.lfs.2026.124723_bb0250","doi-asserted-by":"crossref","first-page":"3163","DOI":"10.1182\/blood.2025029532","article-title":"CD371-targeted CAR t cells secreting interleukin-18 exhibit robust expansion and clear refractory acute myeloid leukemia","volume":"146","author":"Geyer","year":"2025","journal-title":"Blood"},{"key":"10.1016\/j.lfs.2026.124723_bb0255","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1056\/NEJMoa2408771","article-title":"Enhanced CAR t-cell therapy for lymphoma after previous failure","volume":"392","author":"Svoboda","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.lfs.2026.124723_bb0260","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtn.2024.102308","article-title":"First-in-class transactivator-free, doxycycline-inducible IL-18-engineered CAR-t cells for relapsed\/refractory b cell lymphomas","volume":"35","author":"Justicia-Lirio","year":"2024","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.lfs.2026.124723_bb0265","doi-asserted-by":"crossref","DOI":"10.3389\/ebm.2026.10938","article-title":"How can we balance risk and benefit of interleukin-18 armored t cell therapies?","volume":"251","author":"Vicenova","year":"2026","journal-title":"Exp. Biol. Med."},{"key":"10.1016\/j.lfs.2026.124723_bb0270","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.1002\/eji.201142173","article-title":"M-CSF induces the expression of a membrane-bound form of IL \u221218 in a subset of human monocytes differentiating in vitro toward macrophages","volume":"42","author":"Bellora","year":"2012","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.lfs.2026.124723_bb0275","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1007\/s00262-021-02982-9","article-title":"Expansion of cytotoxic natural killer cells in multiple myeloma patients using k562 cells expressing OX40 ligand and membrane-bound IL-18 and IL-21","volume":"71","author":"Thangaraj","year":"2022","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.lfs.2026.124723_bb0280","doi-asserted-by":"crossref","first-page":"180","DOI":"10.3343\/alm.2025.0168","article-title":"Optimization of natural killer cell expansion with k562-mbIL-18\/\u221221 feeder cells and assurance of feeder cell-free products","volume":"46","author":"Jo","year":"2026","journal-title":"Ann. Lab. Med."},{"key":"10.1016\/j.lfs.2026.124723_bb0285","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1016\/j.jcyt.2022.05.004","article-title":"Natural killer cells have a synergistic anti-tumor effect in combination with chemoradiotherapy against head and neck cancer","volume":"24","author":"Jung","year":"2022","journal-title":"Cytotherapy"},{"key":"10.1016\/j.lfs.2026.124723_bb0290","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1038\/s41423-021-00686-9","article-title":"Expanded natural killer cells augment the antimyeloma effect of daratumumab, bortezomib, and dexamethasone in a mouse model","volume":"18","author":"Thangaraj","year":"2021","journal-title":"Cell. Mol. Immunol."},{"key":"10.1016\/j.lfs.2026.124723_bb0295","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1718321","article-title":"Targeting highly attenuated IL-18 to PD-1 for enhanced anti-tumor activity","volume":"16","author":"Zhou","year":"2025","journal-title":"Front. Immunol."},{"key":"10.1016\/j.lfs.2026.124723_bb0300","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1158\/2326-6066.CIR-22-0373","article-title":"Intratumoral gene transfer of mRNAs encoding IL12 in combination with decoy-resistant IL18 improves local and systemic antitumor immunity","volume":"11","author":"Cirella","year":"2023","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.lfs.2026.124723_bb0305","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2016.1274478","article-title":"IL-12, IL-15, and IL-18 pre-activated NK cells target resistant t cell acute lymphoblastic leukemia and delay leukemia developmentin vivo","volume":"6","author":"Boieri","year":"2017","journal-title":"OncoImmunology"},{"key":"10.1016\/j.lfs.2026.124723_bb0310","doi-asserted-by":"crossref","first-page":"3462","DOI":"10.1158\/1078-0432.CCR-07-4740","article-title":"A dose-escalation study of recombinant human interleukin-18 using two different schedules of administration in patients with cancer","volume":"14","author":"Robertson","year":"2008","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.lfs.2026.124723_bb0315","doi-asserted-by":"crossref","DOI":"10.1016\/j.cyto.2025.156979","article-title":"Interleukin-18 (IL-18) engineered for half-life extension and resistance to IL-18 binding protein (IL-18BP) to enhance anti-cancer therapeutic potential","volume":"193","author":"Dreaden","year":"2025","journal-title":"Cytokine"},{"key":"10.1016\/j.lfs.2026.124723_bb0320","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2025-011789","article-title":"Engineered IL-18 variants with half-life extension and improved stability for cancer immunotherapy","volume":"13","author":"Bainbridge","year":"2025","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.lfs.2026.124723_bb0325","doi-asserted-by":"crossref","first-page":"4988","DOI":"10.1016\/j.ymthe.2025.07.004","article-title":"Nanobody-engineered bispecific IL-18 mimetics drive antitumor immunity by engaging CD8(+) t cell and evading IL-18BP in preclinical models","volume":"33","author":"Nan","year":"2025","journal-title":"Mol. Ther.: J. Am. Soc. Gene Ther."},{"key":"10.1016\/j.lfs.2026.124723_bb0330","doi-asserted-by":"crossref","first-page":"943","DOI":"10.21873\/anticanres.17482","article-title":"Elevated plasma interleukin-18 levels in head and neck squamous cell carcinoma: correlation with IL-18 binding protein but not ferritin","volume":"45","author":"Fleckner","year":"2025","journal-title":"Anticancer Res."},{"key":"10.1016\/j.lfs.2026.124723_bb0335","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.21037\/atm-21-6011","article-title":"Identification of a novel pyroptosis-related gene signature correlated with the prognosis of diffuse glioma patients","volume":"9","author":"Zhang","year":"2021","journal-title":"Ann. Transl. Med."},{"key":"10.1016\/j.lfs.2026.124723_bb0340","article-title":"Cerebrospinal fluid immunological cytokines predict intracranial tumor response to immunotherapy in non-small cell lung cancer patients with brain metastases","volume":"13","author":"Li","year":"2023","journal-title":"OncoImmunology"},{"key":"10.1016\/j.lfs.2026.124723_bb0345","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1038\/s41590-023-01475-4","article-title":"TREM2 macrophages drive NK cell paucity and dysfunction in lung cancer","volume":"24","author":"Park","year":"2023","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.lfs.2026.124723_bb0350","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2026-015090","article-title":"Anti-PD1-IL18 immunoconjugate promotes effector t cell-mediated antitumor immunity","volume":"14","author":"Oelgarth","year":"2026","journal-title":"J. Immunother. Cancer"}],"container-title":["Life Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0024320526005321?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0024320526005321?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T05:19:11Z","timestamp":1793769551000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0024320526005321"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":70,"alternative-id":["S0024320526005321"],"URL":"https:\/\/doi.org\/10.1016\/j.lfs.2026.124723","relation":{},"ISSN":["0024-3205"],"issn-type":[{"value":"0024-3205","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Therapeutic engineering of the IL-18-IL-18BP axis for precision cancer immunotherapy","name":"articletitle","label":"Article Title"},{"value":"Life Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lfs.2026.124723","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"124723"}}